Crisugabalin
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Formula | C12H19NO2 |
| Molar mass | 209.289 g·mol−1 |
Crisugabalin (HSK16149) is a selective
GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which as a similar mechanism of action. It is in Phase III trials as of 2023.[1][2] The drug can be administered with or without food.[3]
See also
References
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |